Format

Send to

Choose Destination
Expert Rev Anticancer Ther. 2015;15(12):1473-88. doi: 10.1586/14737140.2015.1108192. Epub 2015 Nov 4.

Massive parallel sequencing in sarcoma pathobiology: state of the art and perspectives.

Author information

1
a Experimental Oncology 1 , CRO Aviano National Cancer Institute , Aviano , PN 33081 , Italy.

Abstract

Sarcomas are an aggressive and highly heterogeneous group of mesenchymal malignancies with different morphologies and clinical behavior. Current therapeutic strategies remain unsatisfactory. Cytogenetic and molecular characterization of these tumors is resulting in the breakdown of the classical histopathological categories into molecular subgroups that better define sarcoma pathobiology and pave the way to more precise diagnostic criteria and novel therapeutic opportunities. The purpose of this short review is to summarize the state-of-the-art on the exploitation of massive parallel sequencing technologies, also known as next generation sequencing, in the elucidation of sarcoma pathobiology and to discuss how these applications may impact on diagnosis, prognosis and therapy of these tumors.

KEYWORDS:

diagnosis; fusion gene; massive parallel sequencing; next generation sequencing; pathobiology; prognosis; sarcoma; therapy

PMID:
26536249
DOI:
10.1586/14737140.2015.1108192
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center